EASD 2024

A real-world study of tirzepatide use in the USA suggests the agent has a similar gastrointestinal adverse event profile to that of GLP-1 receptor agonists.

Liraglutide is more effective at reducing BMI than placebo in children with obesity younger than 12 years old.

Diabetic neuropathy and retinopathy are associated with an increased risk for moderate or severe periodontitis in people with type 2 diabetes.

Canagliflozin shown to lower HbA1c in children with type 2 diabetes and have a similar safety profile to that in adults.

Semaglutide and tirzepatide improve glycemic control and weight loss in people with type 1 diabetes. 

A speech-based AI algorithm correctly predicts type 2 diabetes in patients. 

Tirzepatide may be superior to liraglutide and semaglutide for weight loss in obese patients, but with a greater number of gastrointestinal side effects. 

The higher the percentage of blood glucose values within a “tight limit range”, the lower the number of diabetes complications.

Pooled analysis of three studies with finerenone suggests cardiorenal benefits for patients at high risk for cardiovascular, renal, and metabolic disease.

Semaglutide significantly reduces the risk of progression of kidney disease by 24% versus placebo in adults with type 2 diabetes and chronic kidney disease.

SGLT2 inhibitors appear to provide better protection for neuropsychiatric health than GLP1 receptor agonists and metformin in patients with type 2 diabetes.

Data analysis finds that insulin resistance is linked to 31 diseases, including sleeps disorders, bacterial infections and pancreatitis.

Tirzepatide reduces UACR without adversely affecting eGFR in people with obesity and type 2 diabetes, shows post-hoc analysis of SURMOUNT-2.

Amycretin was safe and reliable in people with obesity but without diabetes, with the highest dose leading to over 13% reduction in bodyweight in 12 weeks.